An Analysis of Seres Therapeutics Inc. (MCRB)’s Potential Price Growth

0
19

Seres Therapeutics Inc.’s filing revealed that its insider Ege David S. unloaded Company’s shares for reported $39745.0 on Oct 31. In the deal valued at $7.93 per share,5,012 shares were sold. As a result of this transaction, Ege David S. now holds 46,734 shares worth roughly $ 0.26 million.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

Then, Nutritional Health LTP Fund Ge bought 8,738,243 shares, generating $27,525,465 in total proceeds. Upon buying the shares at $3.15, the 10% Owner now owns 5,875,711 shares.

Goldman downgraded its Seres Therapeutics Inc. [MCRB] rating to a Sell from a a Neutral in a research note published on Tuesday, July 23, 2021; the price target was decreased to $7 from $24. PT values the company’s stock at a premium of 21.43 to its Tuesday closing price. Chardan Capital Markets also remained covering MCRB and has increased its forecast on March 05, 2021 with a “Buy” recommendation from previously “Neutral” rating. Chardan Capital Markets revised its rating on September 18, 2020. It rated MCRB as “a Neutral” which previously was an “a Buy”.

Price Performance Review of MCRB

On Tuesday, Seres Therapeutics Inc. [NASDAQ:MCRB] saw its stock jump 3.97% to $5.50. On the same session, the stock had its day’s lowest price of $5.20, but rose to a high of $5.60. Over the last five days, the stock has gained 2.61%. Seres Therapeutics Inc. shares have fallen nearly -1.79% since the year began. Nevertheless, the stocks have fallen -26.76% over the past one year. While a 52-week high of $9.49 was reached on 01/03/23, a 52-week low of $2.50 was recorded on 01/19/23. SMA at 50 days reached $6.05, while 200 days put it at $5.34. A total of 0.66 million shares were traded, compared to the trading of 0.67 million shares in the previous session.

Levels Of Support And Resistance For MCRB Stock

The 24-hour chart illustrates a support level at 5.27, which if violated will result in even more drops to 5.03. On the upside, there is a resistance level at 5.67. A further resistance level may holdings at 5.83. The Relative Strength Index (RSI) on the 14-day chart is 48.55, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.01, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 25.00%. Stochastics %K at 44.66% indicates the stock is a holding.

How much short interest is there in Seres Therapeutics Inc.?

A steep rise in short interest was recorded in Seres Therapeutics Inc. stocks on Oct 13, 2022, growing by 1.56 million shares to a total of 4.94 million shares. Yahoo Finance data shows the prior-month short interest on Sep 14, 2022 was 3.38 million shares. There was a rise of 31.58%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 5.61% of the overall stock float, the days-to-cover ratio (short ratio) rose to 4.31.

Seres Therapeutics Inc. [MCRB] – Who Are The Largest Shareholders?

In filings from Fidelity Management & Research Co, it is revealed that the company now owns 18,610,733 shares, or roughly 14.94% of the outstanding MCRB shares. In other words, the investor’s shares have risen by 9,521 from its previous 13-F filing of 18601212.0. Additionally, Federated Global Investment Manag increased 18.36% of its stake after which the total value it holdings stand at $102,643,733, while Janus Henderson Investors US LLC added 108.14% of its stake to hold $62.44 million in the firm. Over the last quarter, The Vanguard Group, Inc. purchased 1,222,512 shares of Seres Therapeutics Inc., while BlackRock Fund Advisors bought 404,270 shares. At present, SSgA Funds Management, Inc. is holding 3,731,521 shares valued at $20.9 million. Eversept Partners LP owned 1,935,825 shares of the company at the time of its most recent 13F filing, worth $10.84 million.

The most recent change occurred on August 18, 2020 when Piper Sandler began covering the stock and recommended ‘”an Overweight”‘ rating along with a $40 price target.

LEAVE A REPLY

Please enter your comment!
Please enter your name here